Detailed entry information

Protein Information (annotations from UniProt)

Database IDHIV0011655
UniProt IDP14784
Primary gene name(s)IL2RB
Synonym gene name(s)unknown
Protein nameInterleukin-2 receptor subunit beta
Protein functionReceptor for interleukin-2. This beta subunit is involved in receptor mediated endocytosis and transduces the mitogenic signals of IL2.
Subcellular locationMembrane;
Single-pass type I membrane protein.
ECO codeClick here for more information.
Amino acid sequence
FASTA format: P14784
Gene Ontology
(Biological Process)
Complete annatation
cytokine-mediated signaling pathway [GO:0019221];
MAPK cascade [GO:0000165];
negative regulation of apoptotic process [GO:0043066];
protein complex assembly [GO:0006461];
signal transduction [GO:0007165];
viral process [GO:0016032]
Gene Ontology
(Molecular Function)
Complete annatation
interleukin-2 binding [GO:0019976];
interleukin-2 receptor activity [GO:0004911];
Ras guanyl-nucleotide exchange factor activity [GO:0005088]
Gene Ontology
(Cellular Component)
Complete annatation
external side of plasma membrane [GO:0009897];
integral component of plasma membrane [GO:0005887];
intracellular [GO:0005622];
membrane [GO:0016020];
plasma membrane [GO:0005886]
Protein-protein interaction109775
Phylogenetic treeP14784
HIV replication factor status Zhou et al., Cell. Host. Microbe., 2008
      unknown
Brass et al., Science, 2008
      unknown
Smith et al., J. Immunol, 2010
      unknown
Interferon-stimulated
gene status
Lu et al., J. Virol., 2011
      Folds changes 8h: unknown; Folds changes 16h: unknown; Tested: unknown;
Schoggins JW and Rice CM, Curr. Opin. Virol., 2011
      Targeted viruses: unknown
      Viral life cycle: unknown
      Mechanism related to antiviral activity: unknown
Anti-viral restriction factor Liu et al., Retrovirology, 2011
      unknown (Triplicates)

Gene Expression Profile       top

            Up-regulated;            Down-regulated

For brief introduction to each study, please go to the help page.

Gene expression during HIV latency

(1). Mohammadi et al., PLoS Pathog., 2014

Differentially expressed transcripts (Pairwise) during latency and subsequent viral reactivation using several agents - Primary CD4+ T-cell based model


DMSO: Dimethyl suloxyde (negative control) - 0.0033% final
SAHA: Vorinostat (Histone deacetylase inhibitor) - 0.5 μM
CD3: TCR Stimulation by IL-2+ antiCD3/anti-CD28 antibodies
IL7: Interleukin-7 based stimulation
DISU: Disulfiram (alcohol dehydrogenase inhibitor) - 0.5 μM
AZA: 5-azacytidine (AZA; DNA methylation inhibitor) - 1 μM
Experimental Condition Log2 Fold Change P value Adjusted P value
AZA vs. CD31.603793253459641.71375115898265e-061.26306393487464e-05
AZA vs. DISU-0.1241027121417750.734638380184690.974560663114398
AZA vs. IL70.3764666235794560.1673734077040260.936456066003024
AZA vs. SAHA-0.2894879666013750.4083977309926390.764450228433208
DISU vs. CD3-1.738321436534633.15701054298678e-062.66902843101418e-05
DISU vs. IL70.4903606575923410.1099494062153940.433878063616249
DISU vs. SAHA-0.1617629737032570.6661746270771080.898517921545065
DMSO vs. AZA0.06419541841789220.8212567791667741
DMSO vs. CD3-1.547434394658882.27046277900822e-061.51013341129178e-05
DMSO vs. DISU0.1875779027361760.5581721997993230.924836638387915
DMSO vs. IL70.3191922175428760.1162851071251540.60594469060204
DMSO vs. SAHA-0.358057837939540.2337739270936980.580812208247464
HIV vs. Mock in Activation0.2257337859576340.7164256395309120.999983755607037
HIV vs. Mock in Latency0.4964439855333560.002748209288453210.137629590744663
IL7 vs. CD3-1.223467686413750.0001819735468766570.000982409481401093
SAHA vs. CD3-1.913897508552151.60136881977024e-071.58350578175443e-06
SAHA vs. IL7-0.6658827681262850.02145178017111620.10495427922733
(2). Iglesias-Ussel et al., J. Virol., 2013

Up and Downregulated transcripts during Latency (Latently infected CD4+ T cells vs Uninfected)- Primary CD4+Tcell based model
Log2 Fold Change P Value
unknown unknown

Gene expression during HIV infection and replication

(1). Imbeault et al., PloS Pathog., 2012

Transcriptomic profiling of HIV-1 infected CD4+ T cells - Primary CD4+ T cells
Experiment type Log2 Fold Change P Value Adjusted P Value
Infected vs. Mock unknown unknown unknown
Infected vs. Bystander unknown unknown unknown
(2). Lefebvre et al., J. Virol., 2011

Transcriptome analysis of T-cell line (Sup T1)
Log2 Fold Change unknown
(3). Li et al., J. Immunol., 2013

Lymphatic tissue
Acute Fold Change Acute P Value Asymt Fold Change Asypt P Value AIDS Fold Change AIDS P Value
unknown unknown unknown unknown unknown unknown
(4). Chang et al., MBio., 2011

Transcriptome analysis of T-cell line (Sup T1)

Derived from Sherrill-Mix et al., BMC Retrovirol., 2015 cross validation
Up-regulated (True) unknown
(5). Sherrill-Mix et al., BMC Retrovirol., 2015

Deep RNA-seq analysis of primary human T cell infected with low passage HIV isolate HIV89.6 - Primary CD4+ T cell based
Test Status Log2 Fold Change P Value
OK 0.239899 0.0862878
(6). Rotger et al., PLoS Pathog., 2010

Genome-wide mRNA expression of CD4+ T cells from HIV-infected patient
(Genes differentially expressed (at adjusted p<0.01) according to the empirical Bayes approach)
Log2 Fold Change P Value
unknown unknown

Proteomic/Transcriptomics studies indicating differentially expressed genes mediated by HIV

(1). Greenwood et al., Elife, 2016

Activated (CD3/CD28) Primary human CD4+ T cells infected with pNL4-3-dE-EGFP. The table shows the complete (unfiltered) TMT (tandem mass tag)-based proteomic time course dataset
6 h 24 h 48 h 72 h RTi
unknown unknown unknown unknown unknown
(2). Navare et al., Virology, 2012

SUP-T1 cell line
FC-4hpi P-value FC-8hpi P-value FC-20hpi P-value Category
unknown unknown unknown unknown unknown unknown unknown
(3). Hyrcza et al., J. Virolo., 2007

Primary human CD4+ and CD8+ T Cells
Affymetrix Prob ID Fold Change In CD8? Category
unknown unknown unknown unknown

Protein Overview       top

Drug-protein Interaction       (annotations from DrugBank)      top

Drugbank ID Drug Name Drug Status Pharmacological Action Drug Action
DB00041 Aldesleukin approved yes agonist
DB00074 Basiliximab approved, investigational unknown antibody
DB00111 Daclizumab approved, investigational yes antibody
DB00004 Denileukin diftitox approved, investigational yes agonist

Protein Secondary Structure       (annotations from PDB)      top

PDB Accession Method Resolution Chain Structure Preview
1ILM Model - B=31-230.
1ILN Model - B=31-230.
2B5I X-ray 2.3Å B=27-240.
2ERJ X-ray 3.0Å B/F=27-232.
3QAZ X-ray 3.8Å B/E/H/K/N/Q/T/W/Z/c/f/i=24-240.
4GS7 X-ray 2.3Å B=27-240.

HIV-1 Interaction       (annotations from NCBI HIV-1 Interaction Database)      top

HIV Partner Interaction Type PubMed
Envelope surface glycoprotein gp120 downregulates 2315327
2843775
9341758
96374779637477
Envelope surface glycoprotein gp120 upregulates 24162774
Tat downregulates 1394441
7734194
Pr55(Gag) induces release of 25240755

Metabolic/Signalling Pathway       (annotations from KEGG database)      top

Pathway Accession Number Description
hsa04060 Cytokine-cytokine receptor interaction - Homo sapiens (human)
hsa04144 Endocytosis - Homo sapiens (human)
hsa04151 PI3K-Akt signaling pathway - Homo sapiens (human)
hsa04630 Jak-STAT signaling pathway - Homo sapiens (human)
hsa04658 Th1 and Th2 cell differentiation - Homo sapiens (human)
hsa04659 Th17 cell differentiation - Homo sapiens (human)
hsa05162 Measles - Homo sapiens (human)
hsa05166 HTLV-I infection - Homo sapiens (human)
hsa05202 Transcriptional misregulation in cancer - Homo sapiens (human)
Menu